About Shreeji Pioneer in radiotracer manufacturing and distribution in India

Pioneer in radiotracer
pioneer in medical diagnostics in India
Company Profile

History

Shreeji was founded in 1990 as a pure-play diagnostics company. Since its inception, it has been deemed a pioneer in medical diagnostics in India. From installing the first CT Scanner in the remote suburbs of Mumbai, to the first Cardiac CT Scanner in Asia, Shreeji has been instrumental in creating markets for the latest technology and products in the country. It has created a benchmark in service delivery.

Establishing the Medical Cyclotron

The idea of a medical cyclotron facility was mooted in 2007. Alarmed by the six-month waitlist for a PET-CT scan for a close family member, on account of the irregular supply of PET radiotracers, Dr. Amit Maniar and his team embarked on a global tour to understand the PET industry. Since PET radiotracers like F18 have a short half-life (~110 minutes), the logistics in terms of delivery becomes complex. The need for a reliable PET radiotracer supplier in India was apparent to Dr. Amit Maniar. This proved to be the terminus a quo for Shreeji.

The project was commercially operational in 2008 despite the innumerable regulatory and technical challenges. To cater to markets beyond road serviceable areas in and around Mumbai, Shreeji along with GE worked hard with the government and airlines to secure the necessary clearances for safe supply of FDG by flight.

With the assurance of FDG supply from Shreeji, PET-CT markets opened up across India in Chennai, Hyderabad, Ahmedabad, Vadodara, Kolkata, Kochi, Jaipur, Indore, Nagpur, and beyond. In 2011, Shreeji accepted the challenge to deliver FDG to Colombo, paving the way for the first PET-CT in Sri Lanka. Similarly, in 2015, our commitment led to the establishment of the first PET-CT in Nepal.

In 2017, Shreeji’s second medical cyclotron facility at IMT Manesar became operational. It was commissioned in a record 9 months – a cGMP-ready facility, a testament to the expertise, project execution capability, and uncompromising commitment to quality.

Between the Mumbai and Delhi facilities, Shreeji currently has an unrivaled distribution network across India making PET radiotracers conceivable and accessible to hospitals/diagnostic centers in cities, towns, and villages.

Our Reach
Colombo

2011

Kochi

2009

Chennai

2008

Visakhapatnam

2019

Bhubaneshwar

2014

Kolkata

2009

Imphal

2020

Guwahati

2020

Jamshedpur

2020

Raipur

2017

Nagpur

2011

Hyderabad

2008

Bengaluru

2013

Belgaum

2019

Miraj

2019

Chiplun

2021

Sangli

2019

Satara

2018

Pune

2008

Mumbai

2008

Nashik

2014

Aurangabad

2013

Surat

2012

Vadodara

2009

Rajkot

2014

Ahmedabad

2009

Udaipur

2021

Indore

2011

Bhopal

2014

Gwalior

2021

Varanasi

2014

Patna

2014

Kathmandu

2015

Gorakhpur

2020

Kanpur

2018

Lucknow

2013

Jodhpur

2020

Jaipur

2010

Mathura

2017

Faridabad

2017

Gurgaon

2017

Ghaziabad

2018

Noida

2018

Meerut

2018

Delhi

2016

Rohtak

2020

Hisar

2017

Mohali

2017

Ludhiana

2018

Jalandhar

2018

Srinagar

2017

Solapur

2021

Kolhapur

2021

Bikaner

2021

Ranchi

2021

Our Resources
Our facilities are state-of-the-art, cGMP-ready, with great focus on automation, personnel safety, regulatory compliance, and quality control. To ensure reliable tracer production and supply, we have invested in backup equipment/redundancies for key processes to minimize breakdowns in the supply chain. Our proprietary digital platform is an integrated solution for patient management, dose delivery, regulatory reporting, invoicing, and much more.
Reliable tracer
Our Strengths

Largest production
capacity in India
and
flexible manufacturing
processes

Widest PET radiotracer
portfolio in India

Shreeji imaging
Largest distribution network in India to handle complex logistics for delivery of PET radiotracers
Shreejiimaging

Project execution
experience for scaling
operations

Our Goal
how is psma pet scan done

At Shreeji, we envision the future of healthcare to be precision care with radiotracers at the forefront of the revolution.

positron emission tomography pet

We seek to leverage our cGMP-ready facilities and distribution network to provide access to the
widest range of novel
tracers and radiotracers, to
arm medical practitioners
with the necessary
information and tools for
precise diagnoses and
bespoke therapy.

positron emission tomography and computed tomography

We are always exploring possibilities to collaborate with academic centers, pharmaceutical companies, and biotech firms to chart new pathways for the future.

positron emission tomography how it works

Ultimately, we aspire to evolve to be a global leader in theranostics with a strong foundation in manufacturing and research.

pet ct scanning services

CSR activities

At Shreeji, we are aware of our responsibility to the community at large and the need for sustainable and inclusive growth. To this end, the Company, in tune with its CSR policy, supports various projects every year.
test

Keeping with our ethos of improving access to the underserved, the company had earmarked funds for promoting healthcare, specifically, reducing child mortality and combating immune deficiency disease among children. The Company has supported the project titled “Diagnosis and Management of Inborn Errors of Immunity and Related Diseases” at the Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai. Primary Immunodeficiencies (PID) are inherited diseases of the immune system, which render these patients susceptible to serious, and often life-threatening infection and cancer. There are more than 10 million children and adults with primary immunodeficiency worldwide; more than one-half million in the U.S., and more than a million in India. A large number of patients with PIDs are not even diagnosed. Generally, PID is more severe in children than in adults. In India, there are very few institutions where patients with PIDs are diagnosed or treated; the majority of patients remain undiagnosed and die, contributing in part to India’s high infant mortality rate.

The project will support the Department of Immunology to, inter alia:

  • Support for IV Immunoglobulin (IVIg) replacement therapy.
  • Support for prophylactic management and targeted drug therapy.
  • Antenatal screening of family with the index patient.
  • To support the academic activities to create awareness of PID in India.

For more information on our products and services, please contact us